Duality of Interest. N.R. has received consultation fees and/or research funding from Novo Nordisk, Eli Lilly, Sanofi, and SomaLogic. E.G.A. is an employee at Novo Nordisk. A.-M.C. is an employee and shareholder at Novo Nordisk. K.H. has received fees for consulting from Novo Nordisk and LeMaitre and funding for research from the Novo Nordisk Foundation. B.L. has received research support from Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Eli Lilly, Madrigal, MSD, Novo Nordisk, and Sanofi, and has received honoraria as a consultant and speaker from Amgen, AstraZeneca, Boehringer Ingelheim, Eli Lilly, and Novo Nordisk. H.S. has received consulting fees and speaker honoraria from Amgen, Amarin, Boehringer Ingelheim, Novo Nordisk, Novartis, Daiichi Sankyo, Eli Lilly, and Cancom, and has received research funding from Boehringer Ingelheim, Novo Nordisk, and Eli Lilly (paid to the Medical University of Graz, Austria). S.T. is an employee and shareholder at Novo Nordisk. S.V. reports receiving research grants and/or speaking honoraria from Amarin, Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Eli Lilly, HLS Therapeutics, Anthos, Janssen, Novartis, Novo Nordisk, Pfizer, PhaseBio, S&L Solutions Event Management, and Sanofi. M.P.B. is the executive director of CPC, a nonprofit academic research organization affiliated with the University of Colorado that receives or has received research grant/consulting funding between August 2021 and the present from Abbott Laboratories, Agios Pharmaceuticals, Alexion Pharma, Alnylam Pharmaceuticals, Amgen, Angionetics, Anthos Therapeutics, ARCA Biopharma, Array BioPharma, AstraZeneca and affiliates, Atentiv, Audentes Therapeutics, Bayer and affiliates, Beth Israel Deaconess Medical Center, Better Therapeutics, Boston Clinical Research Institute, Bristol-Myers Squibb, Cambrian Biopharma, Cardiol Therapeutics, CellResearch, Cleerly, Cook Regentec, CSL Behring, Eidos Therapeutics, EP Trading, EPG Communication Holdings, Epizon Pharma, Esperion Therapeutics, Everlywell, Exicon Consulting, Faraday Pharmaceuticals, Foresee Pharmaceuticals, Fortress Biotech, HDL Therapeutics, Heartflow, Hummingbird Bioscience, Insmed, Ionis Pharmaceuticals, IQVIA, Janssen and affiliates, Kowa Research Institute, Lexicon Pharmaceuticals, Medimmune, Medpace, Merck and affiliates, Nectero Medical, Novartis, Novo Nordisk, Osiris Therapeutics, Pfizer, PhaseBio Pharmaceuticals, PPD Development, Prairie Education and Research Cooperative, Prothena Biosciences, Regeneron Pharmaceuticals, Regio Biosciences, Sanifit Therapeutics, Sanofi-Aventis Groupe, Silence Therapeutics, Silence Therapeutics, Smith & Nephew, Stealth BioTherapeutics, Brigham & Women’s Hospital, The Feinstein Institutes for Medical Research, Thrombosis Research Institute, VarmX, Virta Health, Worldwide Clinical Trials, WraSer Pharmaceuticals, and Yale Cardiovascular Research Group. No other potential conflicts of interest relevant to this article were reported.
PubMed
